How can the Quick to Clinic™ program help deliver your large molecule with speed?

Quick to Clinic™ solution for first-in-human biologic clinical trials

The pressure to file an IND makes accelerated phase I safety testing a priority. With the Quick to Clinic™ program, we can deliver your large molecule drug product for first-in-human studies in as little as 14 months. To help reduce the time it takes to get your discovery to patients who need it, our Quick to Clinic™ for biologics is made with speed in mind.

Large molecule Quick to Clinic™ program

In as little as 14 months, you can have your released biologic drug product ready for your phase I, first-in-human trial. That is six months faster than most standard timelines and includes a minimum of one month of stability data. This innovative solution for biologic molecules provides you with:

Benefits of our large molecule Quick to Clinic™ program

Integrated global network of experts

Our client-focused mindset and global expertise implement a best-in-class integrated offering to position your molecule for greater therapeutic and financial success. Our experience guiding new and emerging clients through each phase of drug development has resulted in saving time and cost.

Our integrated network of technical, quality, and customer engagement teams are ready to support your drug development journey. The Pharma Services network has 55+ sites across five continents and employs approximately 3,500 scientists, technicians, and engineers with deep technical expertise all working together to ensure the success of your molecule. We currently offer manufacturing locations in the United States, Europe, and Australia, which provides you with simplified logistics and R&D tax advantages. We offer a broad range of solutions that include:

Contact us today to find out if your project is right for our Quick to Clinic™ Program.

Additional Resources